These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 21360850

  • 1. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma.
    Yodono H, Matsuo K, Shinohara A.
    Anticancer Drugs; 2011 Mar; 22(3):277-82. PubMed ID: 21360850
    [Abstract] [Full Text] [Related]

  • 2. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
    Maeda N, Osuga K, Higashihara H, Tomoda K, Mikami K, Nakazawa T, Nakamura H, Tomiyama N.
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
    Shirono T, Iwamoto H, Niizeki T, Shimose S, Nakano M, Satani M, Okamura S, Noda Y, Kamachi N, Kuromatsu R, Sakai M, Nomiyama M, Kuwano T, Tanaka M, Koga H, Torimura T.
    Oncology; 2019 Feb; 96(2):79-86. PubMed ID: 30293080
    [Abstract] [Full Text] [Related]

  • 6. Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma.
    Nishikawa H, Osaki Y, Kita R, Kimura T, Ohara Y, Takeda H, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Nishiguchi S.
    Oncol Rep; 2014 Jan; 31(1):65-72. PubMed ID: 24220763
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma.
    Hao MZ, Lin HL, Chen QZ, Hu YB, Chen JB, Zheng JX, Zhou D, Zhang H.
    J Dig Dis; 2017 Jan; 18(1):31-39. PubMed ID: 27987344
    [Abstract] [Full Text] [Related]

  • 9. Suitable blending method of lipiodol-cisplatin in transcatheter arterial embolization for hepatocellular carcinoma: evaluation of sustained release and accumulation nature.
    Takaki Y, Kaminou T, Shabana M, Ihaya T, Otsubo K, Ogawa T.
    Hepatogastroenterology; 2008 Jan; 55(81):202-6. PubMed ID: 18507107
    [Abstract] [Full Text] [Related]

  • 10. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion.
    Kamada K, Nakanishi T, Kitamoto M, Aikata H, Kawakami Y, Ito K, Asahara T, Kajiyama G.
    J Vasc Interv Radiol; 2001 Jul; 12(7):847-54. PubMed ID: 11435541
    [Abstract] [Full Text] [Related]

  • 11. Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma.
    Maeda S, Shibata J, Fujiyama S, Tanaka M, Noumaru S, Sato K, Tomita K.
    Hepatogastroenterology; 2003 Jul; 50(51):809-13. PubMed ID: 12828090
    [Abstract] [Full Text] [Related]

  • 12. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma.
    He M, Li Q, Shen J, Tan G, Li Q, Lai J, Wei W, Zhang Y, Zou R, Chen M, Guo R, Shi M.
    Cancer Med; 2019 Aug; 8(9):4200-4213. PubMed ID: 31207163
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prospective comparison of transcatheter arterial chemoembolization with Lipiodol-epirubicin and Lipiodol-cisplatin for treatment of recurrent hepatocellular carcinoma.
    Sahara S, Kawai N, Sato M, Minamiguchi H, Nakai M, Takasaka I, Nakata K, Ikoma A, Sawa N, Sonomura T, Shirai S.
    Jpn J Radiol; 2010 Jun; 28(5):362-8. PubMed ID: 20585924
    [Abstract] [Full Text] [Related]

  • 17. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization.
    Tanaka T, Ikeda M, Okusaka T, Ueno H, Morizane C, Ogura T, Hagihara A, Iwasa S.
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):683-8. PubMed ID: 17541589
    [Abstract] [Full Text] [Related]

  • 18. Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization.
    Chen CS, Li FK, Guo CY, Xiao JC, Hu HT, Cheng HT, Zheng L, Zong DW, Ma JL, Jiang L, Li HL.
    Oncotarget; 2016 Feb 09; 7(6):7241-52. PubMed ID: 26769845
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic effect of a CDDP-epirubicin-Lipiodol emulsion on advanced hepatocellular carcinoma.
    Ichida T, Kato M, Hayakawa A, Ito S, Mori S, Sato T, Sugitani S, Sato H, Watanabe M, Asakura H.
    Cancer Chemother Pharmacol; 1994 Feb 09; 33 Suppl():S74-8. PubMed ID: 8137488
    [Abstract] [Full Text] [Related]

  • 20. Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial.
    Aramaki O, Takayama T, Moriguchi M, Sakamoto H, Yodono H, Kokudo N, Yamanaka N, Kawasaki S, Sasaki Y, Kubota K, Otsuji E, Tanaka S, Matsuyama Y, Fujii M, ACE 500 study group.
    Eur J Cancer; 2021 Nov 09; 157():373-382. PubMed ID: 34563992
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.